{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease+Psychosis",
    "query": {
      "condition": "Alzheimer's Disease Psychosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 37,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease+Psychosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T04:04:25.426Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06887192",
      "title": "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psychosis Associated With Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ML-007C-MA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapLight Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 300,
      "start_date": "2025-08-15",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06887192"
    },
    {
      "nct_id": "NCT06644573",
      "title": "Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Insomnia",
        "Sleep Deprivation",
        "REM Behavior Disorder",
        "REM Sleep Behavior Disorder",
        "REM Sleep Measurement",
        "Insomnia",
        "Insomnia Related to Specified Disorder",
        "Insomnia Due to Other Mental Disorder",
        "Insomnia Comorbid to Psychiatric Disorder",
        "Insomnia Due to Anxiety and Fear",
        "Insomnia Related to Another Mental Condition",
        "Insomnia Disorders",
        "Idiopathic Hypersomnia",
        "Sleep Disorders, Circadian Rhythm",
        "Post Trauma Nightmares",
        "PTSD - Post Traumatic Stress Disorder",
        "Sleep Quality",
        "Anesthesia",
        "Anxiety",
        "Depression",
        "Mental Health",
        "Alzheimer Disease or Associated Disorder",
        "Parkinsons",
        "Circadian Rhythm",
        "Circadian Dysregulation",
        "PTSD",
        "Post-Traumatic",
        "Post-Traumatic Stress Disorder Complex",
        "Military Combat Stress Reaction",
        "Sleep",
        "Military Activity",
        "Veterans",
        "Shift Work Sleep Disorder",
        "Menopause Related Conditions",
        "Pain",
        "Cancer Pain",
        "Athletes"
      ],
      "interventions": [
        {
          "name": "PROSOMNIA Sleep Therapy™ (PSTx)",
          "type": "PROCEDURE"
        },
        {
          "name": "Anesthesia-Induced Sleep Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Diprivan (propofol), Astra-Zeneca",
          "type": "DRUG"
        },
        {
          "name": "Continuous EEG Monitoring",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Nyree Penn",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-11-01",
      "completion_date": "2026-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 1,
      "location_summary": "Aventura, Florida",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06644573"
    },
    {
      "nct_id": "NCT02392468",
      "title": "Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Placebo matching BI 409306 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BI 409306 50 mg",
          "type": "DRUG"
        },
        {
          "name": "BI 409306 25 mg",
          "type": "DRUG"
        },
        {
          "name": "BI 409306 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2015-04-15",
      "completion_date": "2017-08-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Eatontown, New Jersey • Austin, Texas",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392468"
    },
    {
      "nct_id": "NCT00795730",
      "title": "Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "NSA-789",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-01",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2021-08-20",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795730"
    },
    {
      "nct_id": "NCT01922258",
      "title": "Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation Associated With",
        "Alzheimer's Disease",
        "Alzheimer's Type",
        "Mental Disorder",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole, OPC-34712",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 270,
      "start_date": "2013-09",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2020-11-20",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 28,
      "location_summary": "Imperial, California • Lakewood, California • Long Beach, California + 21 more",
      "locations": [
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01922258"
    },
    {
      "nct_id": "NCT06585787",
      "title": "A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 406,
      "start_date": "2024-09-26",
      "completion_date": "2026-12-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 98,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 67 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06585787"
    },
    {
      "nct_id": "NCT05511363",
      "title": "A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psychosis Associated With Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 410,
      "start_date": "2022-08-23",
      "completion_date": "2026-10-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 58,
      "location_summary": "Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05511363"
    },
    {
      "nct_id": "NCT05309577",
      "title": "Self-Care for Dementia Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aging",
        "Mental Disorder",
        "Eating, Healthy",
        "Physical Inactivity",
        "Prodromal Symptoms",
        "Sleep",
        "Alzheimer Disease",
        "Dementia",
        "Circadian Rhythm Disorders"
      ],
      "interventions": [
        {
          "name": "Behavioral Self-Monitoring + Motivational Interviewing",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-03-07",
      "completion_date": "2025-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309577"
    },
    {
      "nct_id": "NCT01862640",
      "title": "A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation Associated With",
        "Alzheimer's Disease",
        "Alzheimer's Type",
        "Mental Disorder",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole, OPC-34712",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 433,
      "start_date": "2013-07-11",
      "completion_date": "2017-03-15",
      "has_results": true,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 37,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862640"
    },
    {
      "nct_id": "NCT07459660",
      "title": "An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psychosis Associated With Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ML-007C-MA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapLight Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "91 Years",
        "sex": "ALL",
        "summary": "55 Years to 91 Years"
      },
      "enrollment_count": 210,
      "start_date": "2026-03-25",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-06-10T04:04:25.426Z",
      "location_count": 3,
      "location_summary": "Doral, Florida • Miami, Florida",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07459660"
    }
  ]
}